Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;259(12):3569-3578.
doi: 10.1007/s00417-021-05187-z. Epub 2021 May 4.

Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland

Johanna J Zirpel #  1   2   3 , Isabel B Pfister #  1   2   3 , Christin Gerhardt  1   2   3 , Justus G Garweg  4   5   6   7
Affiliations

Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland

Johanna J Zirpel et al. Graefes Arch Clin Exp Ophthalmol. 2021 Dec.

Abstract

Objective: To assess the long-term visual outcomes in eyes with symptomatic diabetic macular oedema (DME) under intravitreal treatment (IVT) in a clinical routine setting.

Methods: Patients with newly diagnosed DME were included in this retrospective study if they had received at least three IVTs and a follow-up period ≥ 2 years. Due to altered treatment patterns since the approval of ranibizumab for DME in 2012, patients were subdivided according to their first IVT before 2013 (group 1) or thereafter (group 2). The primary outcome measure was the evolution of best-corrected visual acuity (BCVA) over time.

Results: Of 217 eyes (191 patients) with DME, 151 eyes (117 patients) fulfilled the inclusion criteria (63 eyes in the first period, 88 in the second period). Mean follow-up time was 7.9 ± 3.1 (group 1) and 4.1 ± 1.4 years (group 2; p < 0.001). Visual gains were similar in the first year (group 1: + 5.3 ± 15.5, group 2: + 7.3 ± 12.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; p = 0.44), but not thereafter (after 2 years in group 1: + 4.4 ± 15.0, group 2: + 8.3 ± 13.0 ETDRS letters; p = 0.038). During the first year, group 1 patients received less clinical examinations (group 1: 6.6 ± 3.3, group 2: 7.5 ± 2.1; p = 0.007) and less injections (group 1: 3.6 ± 2.7, group 2: 6.1 ± 2.7; p < 0.001).

Conclusion: A greater visual gain, in response to more intensive treatment during the first year, was maintained for at least 5 years in group 2 subjects. Our data confirm that in a real-world setting, early intensive treatment results in satisfying long-term visual outcomes.

Keywords: Aflibercept; Anti-VEGF; Consecutive case series; Diabetic macular oedema (DME); Long-term treatment; Ranibizumab; Real-world studies.

PubMed Disclaimer

Conflict of interest statement

JGG acts as advisor for several pharmaceutical companies and contributes to several clinical studies. The underlying manuscript is independent of these activities. The author did not receive direct or indirect support for this study and does not have conflicting interests with the data that are presented herein. None of the other authors reports any potential conflict of interest.

Figures

Fig. 1
Fig. 1
a Evolution of best-corrected visual acuity (BCVA) over time (in ETDRS letters with 85 letters representing a BCVA of 1.0; mean ± standard error (SE)) in the full cohort. The distinctive loss in BCVA after 7 years of follow-up is likely related to an inherent selection bias. All patients not further systematically requiring treatment were referred back to their private ophthalmologists until DME recurrence. b Evolution of best-corrected visual acuity (BCVA) over time (in ETDRS letters; mean ± standard error (SE)) in two groups representing the periods from 2007 to 2012 and from 2013 to 2017
Fig. 2
Fig. 2
a Change in central retinal thickness (CRT) in the full cohort over time (mean ± standard error (SE)). b Change in central retinal thickness (CRT) over time in the different time periods (mean ± standard error (SE)): the more pronounced macular oedema at diagnosis in group 1 provides evidence for a late referral early after introduction of this therapy
See this image and copyright information in PMC

References

    1. Holekamp NM (2016) Overview of diabetic macular edema. Am J Manag Care. 22(10 Suppl):s284-s291. - PubMed
    1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015;2:17. doi: 10.1186/s40662-015-0026-2. - DOI - PMC - PubMed
    1. Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, Pesudovs K, Price H, White RA, Wong TY, Resnikoff S, Taylor HR, Vision Loss Expert Group of the Global Burden of Disease Study Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39(9):1643–1649. doi: 10.2337/dc15-2171. - DOI - PubMed
    1. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145–1152. doi: 10.1001/archophthalmol.2012.1043. - DOI - PubMed
    1. Jan S, Nazim M, Karim S, Hussain Z. Intravitreal bevacizumab: Indications and complications. J Ayub Med Coll Abbottabad. 2016;28(2):364–368. - PubMed

MeSH terms

Substances

LinkOut - more resources